Prognostic Role of Late Gadolinium-enhanced MRI in Confirmed and Suspected Cardiac Sarcoidosis: Meta-analysis

Overview

Journal Int J Cardiovasc Imaging

Publisher Springer

Specialty Radiology

Date 2024 Jul 16

PMID 39012402

Authors

Ryusuke Sekii

Shingo Kato

Nobuyuki Horita

Daisuke Utsunomiya

Affiliations

Soon will be listed here.

Abstract

The prognostic implications of late gadolinium-enhanced (LGE) magnetic resonance imaging (MRI) in the context of cardiac sarcoidosis (CS) have attracted considerable attention. Nevertheless, a subset of studies has undistinguished confirmed and suspected CS cases, thereby engendering interpretative ambiguities. In this meta-analysis, we evaluated the differences in cardiac MRI findings and their prognostic utility between confirmed and suspected CS. A literature search was conducted using PubMed, Web of Science, and Cochrane libraries to compare the findings of cardiac MRI and its prognostic value in CS and suspected CS. A meta-analysis was performed to compare the prevalence of LGE MRI, odds ratios, and hazard ratios for predicting cardiac events in both groups. A total of 21 studies encompassing 24 different populations were included in the meta-analysis (CS: 393 cases, suspected CS: 2151 cases). CS had a higher frequency of LGE of the left ventricle (87.2% vs. 36.4%, p < 0.0001) and right ventricle (62.1% vs. 23.8%, p = 0.04) than suspected CS. In patients with suspected CS, the presence of left ventricular LGE was associated with higher all-cause mortality [odds ratio: 5.70 (95%CI: 2.51-12.93), p < 0.0001, I = 8%, p for heterogeneity = 0.37] and ventricular arrhythmia [odds ratio: 15.51 (95%CI: 5.65-42.55), p < 0.0001, I = 0, p for heterogeneity = 0.94]. In contrast, in CS, not the presence but extent of left ventricular LGE was a significant predictor of outcome (hazard ratio = 1.83 per 10% increase of %LGE (95%CI: 1.43-2.34, p < 0.001, I = 15, p for heterogeneity = 0.31). The presence of left ventricular LGE was a strong prognostic factor in suspected sarcoidosis. However, the extremely high prevalence of left ventricular LGE in confirmed CS suggests that the quantitative assessment of LGE is useful for prognostic estimation.

References

Birnie D, Kandolin R, Nery P, Kupari M . Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J. 2016; 38(35):2663-2670. DOI: 10.1093/eurheartj/ehw328. View

Gilotra N, Okada D, Sharma A, Chrispin J . Management of Cardiac Sarcoidosis in 2020. Arrhythm Electrophysiol Rev. 2021; 9(4):182-188. PMC: 7788397. DOI: 10.15420/aer.2020.09. View

Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt M, Blankstein R . Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016; 6(1):50-63. PMC: 4731586. DOI: 10.3978/j.issn.2223-3652.2015.12.13. View

Aitken M, Chan M, Urzua Fresno C, Farrell A, Islam N, McInnes M . Diagnostic Accuracy of Cardiac MRI versus FDG PET for Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology. 2022; 304(3):566-579. DOI: 10.1148/radiol.213170. View

Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S . Presence of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Among Patients With Suspected Cardiac Sarcoidosis Is Associated With Adverse Cardiovascular Prognosis: A Systematic Review and Meta-Analysis. Circ Cardiovasc Imaging. 2016; 9(9):e005001. PMC: 5449111. DOI: 10.1161/CIRCIMAGING.116.005001. View

Coleman G, Shaw P, Balfour Jr P, Gonzalez J, Kramer C, Patel A . Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2016; 10(4):411-420. PMC: 5237422. DOI: 10.1016/j.jcmg.2016.05.009. View

Aitken M, Davidson M, Chan M, Urzua Fresno C, Vasquez L, Huo Y . Prognostic Value of Cardiac MRI and FDG PET in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. Radiology. 2023; 307(2):e222483. DOI: 10.1148/radiol.222483. View

Stevenson A, Bray J, Tregidgo L, Ahmad M, Sharma A, Ng A . Prognostic Value of Late Gadolinium Enhancement Detected on Cardiac Magnetic Resonance in Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2023; 16(3):345-357. DOI: 10.1016/j.jcmg.2022.10.018. View

Wang J, Zhang J, Hosadurg N, Iwanaga Y, Chen Y, Liu W . Prognostic Value of RV Abnormalities on CMR in Patients With Known or Suspected Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2023; 16(3):361-372. PMC: 11229671. DOI: 10.1016/j.jcmg.2022.11.012. View

10.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

11.

Birnie D, Sauer W, Bogun F, Cooper J, Culver D, Duvernoy C . HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014; 11(7):1305-23. DOI: 10.1016/j.hrthm.2014.03.043. View

12.

Sugisaki K . [Diagnostic Guidelines and Criteria for Sarcoidosis--2006]. Nihon Kokyuki Gakkai Zasshi. 2008; 46(9):768-80. View

13.

Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M . JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis　- Digest Version. Circ J. 2019; 83(11):2329-2388. DOI: 10.1253/circj.CJ-19-0508. View

14.

Deeks J, Dinnes J, DAmico R, Sowden A, Sakarovitch C, Song F . Evaluating non-randomised intervention studies. Health Technol Assess. 2003; 7(27):iii-x, 1-173. DOI: 10.3310/hta7270. View

15.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

16.

Jin Z, Zhou X, He J . Statistical methods for dealing with publication bias in meta-analysis. Stat Med. 2014; 34(2):343-60. DOI: 10.1002/sim.6342. View

17.

Agoston-Coldea L, Kouaho S, Sacre K, Dossier A, Escoubet B, Chillon S . High mass (>18g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Int J Cardiol. 2016; 222:950-956. DOI: 10.1016/j.ijcard.2016.07.233. View

18.

Athwal P, Chhikara S, Ismail M, Ismail K, Ogugua F, Kazmirczak F . Cardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis. JAMA Cardiol. 2022; 7(10):1057-1066. PMC: 9475438. DOI: 10.1001/jamacardio.2022.2981. View

19.

Bravo P, Raghu G, Rosenthal D, Elman S, Petek B, Soine L . Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol. 2017; 241:457-462. PMC: 5469686. DOI: 10.1016/j.ijcard.2017.03.033. View

20.

Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X . Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014; 7(6):1109-15. DOI: 10.1161/CIRCEP.113.000156. View